Clinical Trials on Hepato-splenomegaly

Total 2080 results

Lihir Medical Centre

Withdrawn

Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly (LiHMS)

Malaria | Anaemia | Hyper-reactive Malarial Splenomegaly

Papua New Guinea
Karolinska Institutet

Recruiting

Ultrasound Guided Microwave Ablation of Splenomegaly in Children

Portal Hypertension | Splenomegaly; Congestive, Chronic | Panhematopenia; Splenic

Sweden
University of British Columbia

Completed

Ultrasound Estimation of Spleen Size

Splenomegaly

Canada
University of British Columbia

Completed

Estimation of Spleen by Residents With VScan

Splenomegaly

Canada
National Institutes of Health Clinical Center (CC)

Completed

Spleen Size in Peripheral Blood Stem Cell Donors

Splenomegaly

United States
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) (BioGM1/BioGM2)

Seizures | Mental Retardation | Hepato-splenomegaly | Dysostosis Multiplex

Egypt, Germany, India, Sri Lanka
M.D. Anderson Cancer Center
Incyte Corporation

Not yet recruiting

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Myelofibrosis | Splenomegaly

United States
M.D. Anderson Cancer Center
Onconova Therapeutics, Inc.

Terminated

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

Leukemia | Anemia | Myelofibrosis | Splenomegaly

United States
Brigham and Women's Hospital
General Electric

Completed

Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination

Pleural Effusion | Splenomegaly

United States
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Pompe Disease (BioPompe) (BioPompe)

Lung Disease | Cerebral Aneurysm | Macroglossia | Cardiac Diseases | Obstructive Sleep Apnoea | Muscular Weakness | Hepato-splenomegaly

Germany, India, Sri Lanka
Sanofi

Recruiting

A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen (OPPUS)

Acid SphingoMyelinase Deficiency | Gaucher Disease, Splenomegaly

France
Lisa H. Butterfield, Ph.D.
National Cancer Institute (NCI)

Terminated

Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, Hepatic

United States
Genetron Health
Piedmont Transplant Institute. 1968 Peachtree Road, NW | 77 Building, 6th...

Not yet recruiting

Novel Biomarker Assay for Biomarker Assay for HCC Detection (GTH_HCC)

Hepato-cellular Carcinoma
Bristol-Myers Squibb

Completed

First Line Hepato Cellular Carcinoma (HCC) (BRISK FL)

Hepato Cellular Carcinoma (HCC)

United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czech Republic, France, Germany, Hong Kong, India, Italy, Japan, Korea, Republic of, Mexico, Poland, Puerto Rico, Russian Federation, South Africa, Spain, Sweden, ... and more
Jewish General Hospital

Terminated

The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department

Splenomegaly | Infectious Mononucleosis

Canada
Xijing Hospital
Air Force Military Medical University, China; Health Science Center of Xi'an...

Unknown

Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic Cirrhosis

Liver Cirrhosis | Carcinoma, Hepatocellular | Laparotomy | Splenomegaly

China
CENTOGENE GmbH Rostock

Withdrawn

Biomarker for Sly Disease (MPS VII) (BioSly) (BioSly)

Developmental Delay | Splenomegaly | Hepatomegaly | Skeletal Abnormalities

Germany, India, Sri Lanka, Egypt
Sanofi

Completed

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Myelofibrosis

Japan
Novartis Pharmaceuticals

Completed

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDE225..

Normal Hepatic Function | Impaired Hepatic Function

Belgium, Germany, Israel, Bulgaria, United States
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
Pfizer

Completed

Pharmacokinetics Of Orally Administered Fx-1006A In Subjects With Hepatic Dysfunction

Mild Hepatic Dysfunction | Moderate Hepatic Dysfunction

South Africa
Hong Kong Children's Hospital

Recruiting

Ultrasound Measurements of Hepatic Vasculatures and Hepatic Doppler Assessment of Healthy Children

Portal Vein | Hepatic Veins | Hepatic Artery | Liver Circulation

Hong Kong
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Healthy Volunteers | Moderate Hepatic Impairment | Severe Hepatic Impairment

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Public Hospitals of Paris (DEVINHEF)

Fulminating Hepatic Failure

France
Eisai Inc.

Completed

A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)

Hepatic Impairment | Hepatic Function

United States
Agios Pharmaceuticals, Inc.

Completed

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

Moderate Hepatic Impairment

United States
Vital Therapies, Inc.

Completed

Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure

Fulminant Hepatic Failure

United States
Vital Therapies, Inc.

Withdrawn

Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) (ELAD)

Fulminant Hepatic Failure

United States
Sanofi

Completed

A National Study in Patients With Unexplained Splenomegaly (SMS)

Gaucher Disease | Splenomegaly

France
Bausch Health Americas, Inc.

Terminated

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

Severe Hepatic Impairment

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Hepatic Impairment | Normal Hepatic Function

United States
Cardiox Corporation

Terminated

Liver Function Assessment - Feasibility and Dosing Study

Hepatic Failure
Sohag University

Recruiting

Efficacy of the Triangle Operation on Clinical Outcomes in Patients With Pancreatic Cancer

Hepato-Biliary Precancerous Condition

Egypt
Merck Sharp & Dohme LLC

Completed

Belzutifan (MK-6482) Hepatic Impairment Study (MK-6482-020)

Moderate Hepatic Impairment

United States
EQRx International, Inc.

Completed

An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143

Severe Hepatic Impairment

United States
Pfizer

Completed

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Severe Hepatic Impairment

United States
Takeda

Completed

Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment

Severe Hepatic Impairment

United States
University Hospital, Strasbourg, France

Recruiting

Hydrodissection of the Hepatoduodenal Ligament (Duodenal)

Hepatic Lesions

France
Rennes University Hospital

Completed

Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)

Hepatic Transplantation

France
Maastricht University

Completed

Liver Glycogen Dynamics (LGD)

Hepatic Glycogen

Netherlands
Shire

Completed

Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants

Hepatic Impairment

United States
University of Michigan Rogel Cancer Center

Completed

Assessment Of Liver Function in Patients Undergoing Hepatic Irradiation (IC-Green)

Hepatic Irradiation

United States
Assiut University

Unknown

Implication of Fluid Strategies Upon Hepatic Outcome in Hepatobiliary Surgery

Hepatic Complication
Novartis Pharmaceuticals

Completed

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

Hepatic Failure

United States
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma Corporation

Completed

PK Study in Subjects With Severe Hepatic Impairment (MCI-186-E05 HP)

Healthy | Severe Hepatic Impairment

Czechia, Hungary, Slovakia
Jazz Pharmaceuticals

Completed

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

Hepatic Impairment

United States

Clinical Trials on Hepato-splenomegaly

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations